[Selective progesterone receptor modulators: future clinical applications]

other OA: closed public-domain-us
View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-08

Selective progesterone receptor modulators (SPRMs) are valuable in women's health, primarily by impacting the endometrium to reduce uterine fibroid volume and bleeding, and are being explored for endometriosis and contraception.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Progesterone antagonists belong to the family of selective progesterone receptor modulators. SPRMs already have several applications in women's health. Their main value lies in their effect on endometrium. For example, they can be used to reduce tumor volume and uterine bleeding before uterine myoma surgery. They are also being evaluated for the treatment of endometriosis, and for estrogen-free contraception.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Hormone Antagonists Receptors, Progesterone Breast Neoplasms Breast Neoplasms Endometriosis Endometriosis Female Hormone Antagonists Hormone Antagonists Humans Leiomyoma Leiomyoma Molecular Structure Receptors, Progesterone Uterine Neoplasms Uterine Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
pubmed
last seen: 2026-05-13T22:14:11.755070+00:00
unpaywall
last seen: 2026-06-14T06:15:46.576397+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine